BioCurex, Inc. is a biotechnology company with headquarters in Richmond, British Columbia. The Company is developing products based on patented and proprietary technology in the area of cancer diagnostics. The technology identifies a universal cancer marker known as RECAF. BioCurex has signed licensing agreements for their cancer detection blood tests with Abbott Laboratories (ABT) and Alere (ALR), formerly Inverness Medical Innovations.
RECAF is a molecule that is present on cancer cells. However, it is not detected in significant levels on healthy cells or benign tumor cells. It is the receptor for AFP (Alpha-fetoprotein) and has classification as an oncofetal antigen due to its presence on fetal and malignant tissues. This characteristic makes RECAF a more accurate indicator of cancer than most current tumor markers. AFP is a marker for liver and testicular cancer that was discovered by Dr. Garri Abelev, a member of BioCurex’s Scientific Advisory Board.
RECAF can be used in blood tests to determine if a patient has cancer. The blood test can be formatted for use in large clinical and hospital laboratories on automated instrumentation, or it can be run manually. It can also be formatted as a single use rapid test for point-of-care (POC) use in physicians’ offices, urgent care facilities, and at the bedside. BioCurex is commercializing their technology via licensing arrangements with companies that develop and market diagnostic tests for the large automated clinical laboratory setting, through development and marketing of non-automated clinical laboratory tests, through development of rapid, point-of-care test formats, and through marketing of their OncoPet RECAF test for cancer in companion animals.
In October, BioCurex announced that the Company believes they are positioned to solve the most pressing issues that have led to a U.S. government-backed panel recommending against routine prostate cancer screening using the PSA (Prostate Specific Antigen) test. The panel concluded that the PSA test used for widespread screening for prostate cancer causes more harm than good. BioCurex’s RECAF cancer marker blood test, in extensive studies done over the last several years, has been shown to detect approximately 70 percent of stage I, 76 percent of stage II, 90 percent of stage III, and 100 percent of stage IV prostate cancers, all with very high specificity.
Last Thursday, BioCurex announced that their wholly owned subsidiary OncoPet™ Diagnostics executed an agreement for the distribution of the OncoPet Sample Collection Kit for canine cancer diagnosis with Butler Schein™ Animal Health. Butler Schein Animal Health, a division of Henry Schein (HSIC), is the leading companion animal health distribution company in the United States. With the agreement, Butler Schein is allowed to purchase the OncoPet Sample Collection Kit from OncoPet Diagnostics to resell to their extensive network of veterinary professionals in the U.S.
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment